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What do you think is a non›disease?
Pros and cons of medicalisation
Editor—The BMJ ’s decision to extend par›
ticipatory democracy to the question of dis›
ease is important not so much for the results
but because it happened at all.1
To a previous generation the idea of ask›
ing consumers to decide on these matters
would have been incomprehensible. Doctors
decided which conditions were legitimate
and which should be consigned to the outer
darkness. In the debate about the nature of
neurasthenia at the end of the 19th century
all protagonists were in the medical profes›
sion and their debates were published in
journals. The views of a few well educated
and well heeled patients may be inferred
from diaries and fiction, but their voices
were largely unheard and unheeded.
Now of course medical authority is in
retreat everywhere and the final arbiter of
“non›disease” is fast becoming the patient.
All this is well and good, so why the out›
rage of so many respondents?1 I suspect it
comes from a failure to recognise the differ›
ent concepts of illness and disease.
Taking chronic fatigue syndrome as an
example from the debate,1 few could now
question that it is indeed an illness. It has a
nosological status and is clearly associated
with suffering, ill health, and disability. The
patient’s voice must be and is paramount.
But is it a disease—that is, has a specific
pathological process been identified to
account for the above? Chronic fatigue syn›
drome is not yet a disease because no unam›
biguous evidence has yet been presented
that has commanded widespread accept›
ance by the scientific community, which
remains the arbiter.
Of course, the syndrome may plausibly
make the transition from illness to disease
like many other illnesses have done. Or it
may not. The traffic is not entirely one way in
which illness entities inevitably receive the
stamp of scientific approval, usually after a
period of being falsely labelled as psycho›
logical. Previously apparently sound entities
have lost their disease status under the cold
light of scientific scrutiny.
The concept of labelling also generated
a lot of heat in this debate. People behave
according to the labels that are ascribed to
them, a process seen as largely negative.
Some respondents rightly echo this, citing
examples in which the act of labelling
distress as something medical (pathological)
carries with it a host of adverse
consequences.1 w1›w8
But more commonly the act of giving a
name to symptoms and disability brings
relief.w9›15 The acknowledgement by the
medical profession that a patient’s condition
has a name and is a legitimate illness is
immensely reassuring and enabling. It also
ends the battle of diagnosis—“If you have to
prove you are ill you can’t get well.”w16
Giving a condition a name is an
intervention in itself with costs and ben›
efits.w17 Crudely handled, medicalisation can
perpetuate disability and exclusion. But used
constructively and appropriately it is the first
step towards recovery.
Simon Wessely professor
Department of Psychological Medicine, Guy’s,
King’s College, and St Thomas’s School of
Medicine and Institute of Psychiatry, London SE5
8AF
s.wessely@iop.kcl.ac.uk
References w1›17 are available on
bmj.com
1 Non›disease. Results of ballot, and electronic responses.
bmj.com 2002 (bmj.com/cgi/content/full/324/7334/DC1;
accessed 4 April 2002).
Compiling list of non›diseases is medical
arrogance
Editor—The arrogance of the concept of
compiling a list of non›diseases is breathtak›
ing.1
Had this list been compiled 50 years ago,
which illnesses would have been listed? Mul›
tiple sclerosis, Crohn’s disease, hypothyroid›
ism? The medical community’s inability to
learn from past mistakes—namely, to
acknowledge that most patients are honestly
relating their symptoms and sincerely wish
to recover—will doom generations of inno›
cent people to the kind of humiliation and
insult this ballot encapsulates.
Unable to perceive their own ignorance,
these commentators will enjoy a brief
moment in the spotlight sneering at the
proponents of non›diseases, utterly failing
to advance medical science.
And you wonder why the benighted suf›
ferers of their non›diseases resort to alterna›
tive practitioners.
Anelie J Walsh student
122 Gow Street, Padstow, New South Wales 2211,
Australia
anelie@mac.com
1 Non›disease. Results of ballot, and electronic responses.
bmj.com 2002 (bmj.com/cgi/content/full/324/7334/DC1;
accessed 4 April 2002).
Defining non›diseases to avoid
medicalisation is throwing the baby out
with the bath water
Editor—Having read the list of non›
diseases I am not sure I fully understand the
rationale behind it.1 However, as a person
who experiences chronic fatigue syndrome,
fibromyalgia, obesity, and several other con›
ditions included on the list I have a vested
interest in the outcome.
I agree that the medicalisation of certain
diseases, illnesses, and conditions has
impacted negatively on those who experi›
ence them. I also accept that it might be bet›
ter not to treat certain conditions in certain
circumstances. This is true of both diseases
and non›diseases and I see no automatic
correlation between disease and treatment
and non›disease and no treatment.
Few people would probably argue that
having big ears is a disease, so its inclusion as
a non›disease poses few problems. This does
not mean, however, that it automatically
requires no treatment. That decision surely
depends on various factors, including the
extent to which the condition impinges on
the life of the person experiencing it.
Conversely, cancer is (arguably) a disease
that often benefits from highly aggressive
treatment, but in some cases less aggressive
treatment or no treatment at all might be
better.
Moreover, despite the best efforts of cer›
tain egotistical members of the medical pro›
fession to convince us that they have all the
answers, many conditions are not under›
stood enough to be able to label them
disease or non›disease. Perhaps a condition
should be labelled a non›disease rather than
erroneously be called a disease. I think, how›
ever, that any rush to label a condition of
unknown origin a non›disease could have
negative effects.
Historically, conditions that have no
known origin have attracted labels such as
psychosomatic and psychological, stigmatis›
ing those experiencing them as lacking or
weak at best and mad at worst and defining
treatment. For example, before the organic
origin of multiple sclerosis was discovered
patients were often labelled as having
psychological difficulties and treated inap›
propriately. This is still the case with
conditions such as chronic fatigue syndrome
and myalgic encephalitis.
Labelling conditions as non›diseases
could also have more far reaching conse›
quences. In the United Kingdom a person’s
entitlement to receive state and other
benefits when unable to work because of ill
health is largely dependent on the recogni›
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tion of a pre›existing condition. Clearly, the
label of non›disease might well negatively
affect the amount of benefit paid.
The classification of certain conditions
as non›diseases to avoid the perils of
medicalisation seems to be a case of
throwing the baby out with the bath water. A
holistic social approach to illness and
disability that treats each person individually
is far better than seeking a cover all solution
replacing one label with another.
Dianna Dunbar graduate in health and community
studies
Yeovil BA21 3SB
uk_leokat@yahoo.com
1 Non›disease. Results of ballot, and electronic responses.
bmj.com 2002 (bmj.com/cgi/content/full/324/7334/DC1;
accessed 4 April 2002).
Labels create legitimacy and produce
dependence
Editor—The last decade has seen the devel›
opment of an ever increasing role of
patients as the primary decision maker in
the management of illness. This approach
has been encouraged by advocacy groups,
the popular news media, and doctors who
cater to the non›critical thinking population.
For those not trained to reign in their
innate belief engines, the association of
symptoms with a disease is encouraged only
by the production of labels. A symptom
complex described by physicians as fibromy›
algia, which is nothing more than a descrip›
tive term for pain in muscles and fibrous
tissue, now has the legitimacy of a disease as
opposed to a panoply of symptoms. The
near mass hysteria displayed by like›minded
believers when these labels are challenged
adds to the dependency on the labels as
being legitimate.
Having evolved a mind that is designed
for pattern recognition, resists changing
beliefs in the face of new information, and
encourages the production of cause and
effect relations in the presence of associative
phenomena, some human beings will always
need labels to support their continued
suffering in an unfair world. These non›
diseases clearly contribute to the develop›
ment of co›dependent suffering.
Kevin C Murphy medical oncologist
BC Cancer Agency/Fraser Valley, 13750 96th
Avenue, Surrey, British Columbia, Canada
V3V 1Z2
kmurphy@bccancer.bc.ca
Diet, lifestyle, exercise, spirituality,
and the search for meaning are ignored
at our peril
Editor—Much evidence supports the
organic nature of many of the diseases men›
tioned in the list of non›diseases, particularly
for myalgic encephalitis›chronic fatigue syn›
drome, fibromyalgia, and multiple chemical
sensitivity.1 Evidence also supports shared
symptoms in these and other medically puz›
zling and taxing disorders such as Gulf war
syndrome and irritable bowel syndrome.
Linus Pauling argued that all diseases
have a molecular basis. The validity of this
statement is substantiated by many who
advocate the existence of non›diseases. Yet
in prescribing antidepressants, antiepileptic
drugs, and agonists and antagonists of the
major biogenic amines and neurotransmit›
ters, they are changing the underlying
physicochemical and physiological proper›
ties of organs and body systems, particularly
the brain.
Illich has written perceptively about the
medicalisation of life and its origins and
consequences. Medical ignorance and arro›
gance dominated by rationalism seeks
explanations of puzzling signs and symp›
toms and ends up creating spurious diseases
and disorders that put the blame on patients
or their caring family and friends.
Numerous examples of, and articles
about, non›diseases were published in the
medical peer reviewed literature by eminent
people of their day. They were wrong. The
advancement of scientific and medical
knowledge has now identified the under›
lying biochemical and physiological disor›
ders of, for example, diabetes, parkinsonism,
and multiple sclerosis. The sufferings of
patients imposed by these arrogant and
rigid attitudes demean both patients and
doctors and create mistrust.
The consequence of the triumph of such
attitudes is now seen in the abandonment of
any responsibility for one’s own health. Life›
styles, however destructive, are pursued in
the belief that medicine will somehow
provide an answer. The drug industry and
much of modern medicine seek new agents
to modify or offset the consequences of
excesses—for example, new anti›obesity
agents for the epidemic of obesity and
maturity onset diabetes.
The food industry also contributes to
modern health problems with the wide›
spread use of pesticides, plant and animal
hormones, and genetically modified crops.
Thus, even eating a healthy diet leads to an
increasing burden of new man›made toxins,
many of which have not been toxicologically
assessed.
Diet, lifestyle, exercise, spirituality, and
the search for meaning are all parts of our
human condition. We ignore them at our
peril.
What is required is a change of heart
and mind leading to a change of practice
that embraces human values of mutual
respect, careful listening, and use of modern
drugs effectively and not randomly. It also
needs to recognise the possible benefits of
alternative treatments in constructive and
critical ways, examine diet and nutrition, and
allow patients to decide how they live and
die with their illness.
Let’s return to being fully human.
Malcolm Hooper emeritus professor of medicinal
chemistry
University of Sunderland, Sunderland SR2 7EE
malcolm.hooper@virgin.net
1 Non›disease. Results of ballot, and electronic responses.
bmj.com 2002 (bmj.com/cgi/content/full/324/7334/DC1;
accessed 4 April 2002).
Summary of responses
Editor—There were some who thought the
exercise a joke, and in bad taste at that.1 Oth›
ers couldn’t see the point and complained
that deciding what was, or was not, a
non›disease was unworthy of a serious
medical journal and did little more than toy
with semantics.
And some thought that the process trivi›
alised genuine suffering and was an excuse
for airing prejudice and ignorance. The
stigma of having a non›disease could only
make that suffering worse. But aside from
the long list of possible contenders—from
burnout to fibromyalgia, and high
cholesterol—the issue provoked vigorous
debate about the purpose of medicine and
what some saw as a narrow understanding
of illness and the limited scientific paradigm.
Respondents struggled with definitions
of their own, and Kazem Zarrabi, a postdoc›
toral researcher at the University of Lund,
Sweden, suggested that we should look to
Darwin for guidance, regarding as disease
any condition that interfered with our
reproductive success and compromised our
“inclusive fitness.”
Medicalising natural processes, such as
normal childbirth, the menopause, and
bereavement was not a healthy option,
countered several correspondents, serving
to boost the profits of drug companies.
And much of what we classify as disease
is really a byproduct of ageing, suggested
Dirk Ulbricht of the Centre Hospitalier,
Luxemburg, including osteoporosis, said
Iona Collins, specialist registrar in trauma at
the John Radcliffe Hospital, Oxford.
But de›medicalising disease could deny
those who had them the right to research
and treatment, said Alex McLaughlin, a
writer from Red Hill in Australia, and they
could be dismissed as “somatisers.” The nub
of the issue, she said, was whether medicine
had the capacity and the moral authority to
define what is and what isn’t disease.
Others suggested that labels helped
people cope better, gave them legitimacy,
and signalled protected funding and physi›
cian time. Chronic fatigue syndrome was
frequently suggested as rightfully belonging
to the non›disease category, but it was also
vigorously defended as having clear physio›
logical changes.
And there were fears that state funding
for disease that impaired mobility and the
ability to work might be withheld if it were to
lose its legitimate label. The UK govern›
ment’s refusal to recognise repetitive strain
injury as a disease, suggested Martin Wilson
of Glasgow, denied people financial help.
Respondents worried that definitions
were founded on shaky ground, guided as
they are by constantly changing criteria:
(lack of) knowledge, different cultural per›
spectives, where you lived.
And they were also subject to fads and
fashion. A case in point is obesity, which was
regarded as a sign of prosperity a century
ago, pointed out research professor of
chemistry, Joel Kaufmann, from Philadel›
phia. New Zealand patients’ rights cam›
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paigner Gurli Bagnall was concerned about
the prevalence of attention deficit disorder
and the way in which Ritalin (methylpheni›
date hydrochloride) had been heavily
promoted as a suitable treatment for it.
But several people suspected that the
proposed list conveniently included many
non›diseases for which there was little effec›
tive treatment, and even less understanding
of their cause.
Public health physician Steve Hajioff
commented: “This has been the case for
many conditions throughout history . . .
Crohn’s disease, multiple sclerosis, and
coeliac disease are good examples.” Others
given were asthma and lupus.
Raymond Colliton of Philadelphia
pointed out that the purpose of medicine
was to reduce human suffering, irrespective
of the labels given. And Elmer Fudd agreed
that “disease is a very slippery concept,” but
added “So is medicine.”
Caroline White freelance medical journalist
London
1 Non›disease. Results of ballot, and electronic responses.
bmj.com 2002 (bmj.com/cgi/content/full/324/7334/DC1;
accessed 4 April 2002).
Editorial on CFS was biased,
inaccurate, and misleading
Editor—As a member of the chief medical
officer’s working group on chronic fatigue
syndrome, I consider that Straus has failed
to appreciate the difficulties of deciding what
constitutes evidence in an illness as uncer›
tain and heterogeneous as this.1 He also
misunderstood, or took out of context, some
of the key conclusions and recommenda›
tions in the chief medical officer’s report.
Although it was agreed that evidence
should not just be limited to the results of
randomised controlled trials, the findings of
the York systematic review were frequently
cited. It was therefore disingenuous of
Straus to state that information from this
review did not influence the report’s conclu›
sions about a wide range of therapeutic
interventions. It did.
Equally, it would have been a serious
omission if the report had failed to refer to
the feedback from patients contained in
three large surveys on attitudes to manage›
ment, as well as two events where patients
and carers met with the working group. All
three surveys concluded that graded exer›
cise as is currently being done made more
people worse than any other intervention.
Pacing, however, was found to be beneficial
by around 90% of respondents. By dismiss›
ing such views as anecdote, Straus fails to
appreciate that the Department of Health is
encouraging patients to enter into a
therapeutic relationship with the medical
profession in the management of chronic
conditions such as this.2
The recommendation that an incipient
diagnosis of chronic fatigue syndrome
should be considered after six weeks of char›
acteristic symptomatology was taken out of
context. Current diagnostic criteria for the
syndrome have been heavily criticised for
their emphasis on selecting patients for
research rather than routine clinical assess›
ment, and there was widespread agreement
that early diagnosis with advice on manage›
ment could reduce long term morbidity.
Does Straus believe that these patients
should have to endure six months of quite
severe ill health before they can be offered a
presumptive diagnosis and advice on man›
agement? The report clearly concluded that
this should no longer be the case.
Despite his generally dismissive view of
much of the section on management, Straus
nevertheless welcomes the main conclusion:
that this is a genuine and disabling illness
that can no longer be ignored by clinicians
and researchers.
Charles Shepherd medical adviser
ME Association, Buckingham MK18 1TH
charlesbshepherd@lineone.net
1 Straus SE. Caring for patients with chronic fatigue
syndrome. BMJ 2002;324:124›5. (19 January.)
2 Department of Health. The expert patient: a new approach to
chronic disease management for the 21st century. London: DoH,
2001. www.doh.gov.uk/health›inequalities/ep_report.pdf
Gulf war syndrome may be
post›conflict dysfunction
Editor—We have read the results of the
questionnaire based study by Chalder et al
from the Gulf war research unit at King’s
College.1 They found that 17% of the 2961
Gulf war veterans believe themselves to be
suffering from Gulf war syndrome, although
the group has found no evidence to support
such a syndrome.2 The veterans’ belief was
reinforced if they knew someone with
similar symptoms. We believe that this
represents post›conflict dysfunction
expressed according to health beliefs pre›
vailing at the time the questionnaire was
administered.
Hyams et al investigated the health of
veterans without organic disease from
conflicts since the American civil war
(“disordered action of the heart”).3 He
showed that veterans complained of a range
of physical and cognitive symptoms, the
nature of which was independent of the
conflict and gained diagnoses based on the
then current aetiological beliefs. The Gulf
veterans’ medical assessment programme of
the Ministry of Defence now provides a
robust clinical base.4 Of the 3000 who have
attended (6% of the deployed force), 80%
are well. The 20% who are ill account for
about 1% of the deployed force.
Unwin et al showed that self reported
physical functioning in Gulf veterans is
broadly similar to that in a control group of
non›deployed forces and Bosnia veterans
but that the perceived quality of their health
is reduced.5 The difference between the 17%
of Chalder et al and our clinical findings
may be explained by the disordered health
perception and related behaviour.1 We think
that this, and the syndromes discussed by
Hyams and others, constitutes post›conflict
dysfunction.3
Chalder et al speculate that social
networks, usually protective of health,
worked perversely in the case of the Gulf
war veterans. A major omission in their dis›
cussion was a lack of consideration of the
role of the media in reporting Gulf veterans’
illnesses. Although we are not suggesting
that the media are solely the “infective
agent,” their function as the “vector” of
disease in the Gulf war syndrome deserves
comment. Media distortion and oversimpli›
fications of the issues are the rule and were
exemplified when the Daily Telegraph of 31
August 2001, commenting on the paper by
Chalder et al, ran the headline “One in six
veterans has Gulf war syndrome.” We have
taken histories from many veterans who
attended the medical assessment pro›
gramme because of fears fanned by ill
informed and unbalanced media specula›
tion. Some of these men have post›conflict
dysfunction, but no Gulf war syndrome.
Roger Gabriel consultant physician, Gulf veterans’
medical assessment programme
J P G Bolton medical adviser
Amanda J Bale database manager, Gulf veterans’
medical assessment programme
Harry A Lee head, Gulf veterans’ medical assessment
programme
Gulf Veterans’ Illnesses Unit, Ministry of Defence,
London SE1 0TD
1 Chalder T, Hotopf M, Unwin C, Hull L, Ismail K, David A,
et al. Prevalence of Gulf war veterans who believe they
have Gulf war syndrome: questionnaire study. BMJ
2001;323:473›6. (1 September.)
2 Ismail K, Everitt B, Blatchley N, Hull L, Unwin C, David A,
et al. Is there a Gulf war syndrome? Lancet 1999;353:179›82.
3 Hyams KC, Wignall FS, Roswell R. War syndromes and
their evaluation: from the US civil war to the Persian Gulf.
Am Intern Med 1966;125:398›495.
4 Lee HA, Gabriel R, Bale AJ, Bolton JPG, Blatchley N. Clini›
cal findings of the second 1000 UK Gulf war veterans who
attended the Ministry of Defence’s medical assessment
programme. JRAMC 2001;147:153›60.
5 Unwin C, Blatchley N, Coker WJ, Ferry S, Hotopf M, Hull
L, et al. The health of United Kingdom servicemen who
served in the Persian Gulf war. Lancet 1999;353:169›78.
ICD and DSM are
contemporary cultural
documents
Editor—In their riposte to my critique of
post›traumatic stress disorder Mezey and
Robbins cite me as advocating a “stiff upper
lip” approach to adversity.1 2 This is disin›
genuous: I was pointing to the tension
between aspects of British identity tradition›
ally grounded in stoicism and composure
and the emergent demands of an expressive
individualism.
Mezey and Robbins pay lip service to the
role of social factors, but their argument
runs the other way. Their core defence is
institutional: post›traumatic stress disorder
must be valid because it is in the books—in
psychiatric classification systems such as the
International Classification of Diseases (ICD)
and the Diagnostic and Statistical Manual of
Mental Disorders (DSM). By this token they
would happily have diagnosed homosexual›
ity as a mental illness during the years when
it was classified as such in the ICD or DSM.
Psychiatrists serve neither society nor
patients with psychiatric difficulties when they
uncritically endorse the medicalisation of life
Letters
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(though they may well serve the pharmaceu›
tical industry, with its vested interest in the
medicalisation of the human predicament:
some antidepressants are now being specifi›
cally marketed for post›traumatic stress disor›
der). It is academic shallowness and compla›
cency that may permit sociocultural (and
often political) values and expectations to be
dressed up as medicopsychiatric facts.
What comes to be presented as psychiat›
ric knowledge is as much constructed as dis›
covered. The ICD and the DSM categorise
phenomenological constellations, but this is
not synonymous with scientific validation.
The classifications are not atheoretical and
value free—for example, they contain onto›
logical notions of what constitutes a real dis›
order, epistemological notions about what
counts as scientific evidence, and method›
ological notions about how research should
be conducted.3 They are contemporary
cultural documents. Awareness of this helps
refine our clinical gaze.
Derek Summerfield consultant psychiatrist
CASCAID, South London and Maudsley NHS
Trust, London SE1 1JJ
1 Mezey G, Robbins I. Usefulness and validity of post›
traumatic stress disorder as a psychiatric category. BMJ
2001;323:561›3. (8 September.)
2 Summerfield D. The invention of post›traumatic stress dis›
order and the social usefulness of a psychiatric category.
BMJ 2001;322:95›8.
3 Mezzich J, Kirmayer L, Kleinman A, Fabrega H, Parron D,
Good B, et al. The place of culture in DSM IV. J Nerv Ment
Dis 1999;187:457›64.
Non›cardiac chest pain
Patients need diagnoses
Editor—We are concerned about one of the
sweeping conclusions in the editorial on
non›cardiac chest pain.1 We do not agree
that “providing a diagnosis may be less
important than addressing a patient’s con›
cerns and fears.” Providing a diagnosis is
probably the most important part of the
care of such patients.
Evidence shows that angiography fails to
relieve the anxiety of patients,2 but the
psychological and psychiatric complications
of chest pain may be at least partially related
to general practitioners’ inability to provide
a definite diagnosis. Continued prescription
of antiangina drugs, and possibly failure to
investigate further, contribute to continued
anxiety. Patients with chest pain of non›
cardiac origin need a label to hang on to.
Because there is often more than one
diagnosis, we suggest using the label “chest
pain of unexplained origin.” A multidiscipli›
nary approach could be useful, with particu›
lar attention being paid to psychological
factors.3 Nijher et al say that an alternative
non›cardiac diagnosis can be difficult to
make, but it is often possible: a definite diag›
nosis can be reached in up 85% of patients.4
The impact of chest pain clinics is uncertain,
and follow up for patients with non›cardiac
chest pain may be of value.5 Certainly, as the
authors say, these clinics might worsen the
situation if adequate follow up is not
arranged.
Adequate investigation for other physi›
cal causes of chest pain must be part of a
comprehensive approach to this difficult
problem.
David S Coulshed staff specialist in cardiology
Department of Cardiology, Nepean Hospital,
Penrith, New South Wales 2751, Australia
Guy D Eslick gastroenterology fellow
eslickg@med.usyd.edu.au
Nicholas J Talley professor of medicine
Department of Medicine, University of Sydney,
Nepean Hospital, PO Box 63, Penrith
1 Nijher G, Weinman J, Bass C, Chambers J. Chest pain in
people with normal coronary anatomy. BMJ 2001;
323:1319›20. (8 December.)
2 Ockene IS, Shay MJ, Alpert JS, Weiner BH, Dalen JE.
Unexplained chest pain in patients with normal coronary
arteriograms: a follow›up study of functional status.N Engl
J Med 1980;303:1249›52.
3 Clouse RE, Lustman PJ. Psychiatric illness and contraction
abnormalities of the esophagus. N Engl J Med 1983;309:
1337›42.
4 Vantrappen G, Janssens J. Angina and esophageal pain—a
gastroenterologist’s point of view.Eur Heart J 1986;7:828›34.
5 Eslick GD, Coulshed DS. Rapid assessment of chest pain.
BMJ 2002;324:422. (16 February.)
Rapid access clinics lead to deskilling of
general practitioners
Editor—In many ways the editorial about
non›cardiac chest pain indicates the increas›
ing problem of overspecialisation.1 General
practitioners are good at stopping the
juggernaut of investigation at source, but
this takes nerve and is sometimes seen as
not doing enough. Of course the general
practitioner who boldly states that chest pain
is non›cardiac at the first consultation is not
seen to be doing very much; the decision
may be made on no more than a hunch and
experience, but the potential savings in time,
money, and neuroses are huge. The trouble
is that the system is unforgiving if the hunch
was wrong.
Rapid access clinics, be they for chest
pain, breast lumps, or rectal bleeding, deskill
general practitioners in dealing with these
symptoms because they give easy access to
decisions taken with much more infor›
mation. However, the editorial shows the
negative side of this process. Our hospital
colleagues are less good at taking decisions
with no tests, as they have to be seen to be
doing everything.
I have always thought that the general
practitioner system works well only because
general practitioners half do things, but the
benefits to patients can be huge and the
savings immense. It is a question of where to
draw the line. Deciding that there is probably
nothing wrong takes nerve and courage.
Rapid access clinics deskill this process, and
the implications for the NHS are consider›
able in terms of resources. It is not helped by
empire builders who state in the public
domain that patients with certain symptoms
always need extensive investigation and refer›
ral. It leaves general practitioners even more
exposed.
Graeme M Mackenzie general practitioner
Maryport, Cumbria CA15 8EL
g.mackenzie@eidosnet.co.uk
1 Nijher G, Weinman J, Bass C, Chambers J. Chest pain in
people with normal coronary anatomy. BMJ 2001;
323:1319›20. (8 December.)
Hormone replacement therapy
and the breast
Studies must determine the evidence
Editor—As active members of the Australa›
sian Menopause Society, we are disap›
pointed at the conclusions that Dixon drew
in his editorial on hormone replacement
therapy and the breast.1 Although it may be
true that hormone replacement therapy
makes mammograms harder to interpret, it
is far from clear that it causes breast cancer.
A recent overview by Bush et al empha›
sises the weakness of Dixon’s argument,
based, as it is, almost entirely on level three
observational studies.2 Unlike Dixon’s selec›
tion of studies with the highest odds ratio,
Bush et al’s review was of 45 studies
assessing the association between use of
hormone replacement therapy and risk of
breast cancer. It found that risk was reduced
(relative risk < 0.9) in 20% of the studies, did
not change in 47% (0.9›1.1), and increased
in 33% (1.1›2.0). In no study did relative risk
increase above 2.0, and in the 20 studies
where the relation between risk of breast
cancer and combined oestrogen and pro›
gestin therapy was studied only four
reported a significant difference in relative
risk, with two showing an increased and two
a decreased risk.
The heterogeneity of these data is in
stark contrast to the homogeneity of the
data on mortality from breast cancer in
users of hormone replacement therapy that
were reviewed: all 11 of the studies reported
a reduction in risk. Unlike Dixon, the
authors concluded that the likelihood of an
adverse effect of hormone replacement
therapy on breast cancer must be small.
The Australasian Menopause Society is
a sponsor of the women’s international
study of long duration oestrogen use after
the menopause (the WISDOM trial), a large
prospective 15 year randomised placebo
controlled trial. The results of this trial,
together with those of the women’s health
initiative in the United States, will be needed
to answer the question of whether hormone
replacement therapy has any effect (benefi›
cial or adverse) on breast cancer.
Until then strong opinions will continue
to be held about hormone replacement
therapy and its relation to risk of breast can›
cer, often derived from selective quoting of
the available literature. These opinions
heighten the anxiety of women who have
valid reasons for taking hormone replace›
ment therapy and do not afford them the
opportunity of informed choice.
Alastair H MacLennan professor of obstetrics and
gynaecology
Women’s and Children’s Hospital, University of
Adelaide, Adelaide, South Australia, Australia
Beverley Lawton principal investigator
WISDOM New Zealand, Wellington School of
Medicine and Health Sciences, University of Otago,
New Zealand
Rodney J Baber clinical senior lecturer in obstetrics
and gynaecology
University of Sydney, Royal North Shore Hospital,
Sydney 2065, New South Wales, Australia
rbaber@mail.usyd.edu.au
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Women still want to have hormone
replacement therapy
Editor—I was dismayed to read Dixon’s
editorial about hormone replacement
therapy and its effect on the breast1 and have
been provoked to respond by the anguished
cries for help by both patients and
colleagues. Dixon, in the words of Bernard
Levin, has become a single issue fanatic.
There’s more to women’s health concerns
than breast cancer.
Frightening women off hormone
replacement therapy could have many
unpredicted consequences. The lifetime risk
for women of dying of breast cancer is only
1 in 26, with between three and 10 times that
risk of dying from heart disease, depending
on whether they are smokers or non›
smokers.2 For all we know, hormone
replacement therapy could protect more
women from death due to cardiovascular
disease and osteoporotic fractures than the
worst estimates for the increased incidence
of breast cancer. Furthermore, as Dixon
concedes, many of these cancers in women
receiving hormone replacement therapy are
of a favourable phenotype. It is therefore
altogether perverse to criticise hormone
replacement therapy for making screening
mammograms uninterpretable.
Surely, given an informed choice, most
women would be glad of the excuse to opt
out of the national screening programme,
which is of questionable value,3 in favour of
an intervention that improves short term
and long term quality of life. Of course many
women taking hormone replacement
therapy have mastalgia and nodularity, but
most of my patients are happy to live with
this in exchange for the sense of wellbeing
that they get from taking the therapy.
Hormone replacement therapy also
improves skin elasticity, mood, sexuality, and
cognitive function.4
Are we really asking women to give all
this up so as to make the life of our screen›
ing radiologists more comfortable?
Michael Baum emeritus professor of surgery
University College London, CRC/UCL Cancer
Trials Centre, London NW1 2ND
m.baum@ctc.ucl.ac.uk
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Author’s reply
Truth or tact? You have to choose, most times
they are not compatible
Eddie Cantor
Editor—The recent qualitative review by
Bush et al is the basis of the objections of
Baber et al to the conclusions I drew on the
effects of hormone replacement therapy on
the breast of postmenopausal women.1
This review took no account of the quality
of studies included, it did not consider type of
hormone replacement therapy used, its mode
of delivery, or the age at which women started
taking it. Figure 2 in their publication did,
however, confirm that four of the five most
recently published studies have shown an
excess risk of breast cancer for combined
regimens in postmenopausal women. Bush et
al doubt whether oestrogen is important in
breast cancer development and propose that
some additional, as yet unidentified, factor is
secreted from the ovary.
New data from over 9300 women with
early breast cancer randomised to receive
five years of treatment with adjuvant
tamoxifen alone, anastrozole alone, or
tamoxifen and anastrozole combined were
presented last year by Baum. They show that
after 33 months, there were five new invasive
contralateral breast cancers in the 3112
patients taking anastrozole compared with
30 in 3116 women receiving tamoxifen and
23 in 3125 in the combination arm—a
significant reduction in contralateral breast
cancers with anastrozole compared with
tamoxifen (hazard ratio 0.42 (0.22›0.79),
P = 0.0054). These data explode the myth of
an unknown factor proposed by Bush et al
and confirm the importance of oestrogen in
the development of breast cancer.
It was not my intention to try to frighten
women off taking hormone replacement
therapy. The US Food and Drug Administra›
tion removed the treatment of osteoporosis
as an indication for oestrogen replacement
therapy in 1999 because of lack of evidence
from randomised trials. There are new
specific and better drugs for this condition.2
“Hormone replacement therapy should not
be prescribed for the express purpose of pre›
venting cardiovascular disease.”3 In the heart
and oestrogen/progestin replacement study
women over 65 taking hormone replacement
therapy had worsening urinary incontinence
and an increased risk of fatal stroke.4
Baum is inconsistent. He believes that
women should be provided with all available
data on screening so that they can make an
informed choice yet he would deny them all
available information on hormone replace›
ment therapy. There is no doubt that oestro›
gen significantly improves the quality of
many women’s lives. The challenge for
women and their clinicians remains to
control menopausal symptoms and to
deliver the benefits of oestrogen while mini›
mizing the problems that continue to be
reported with these preparations.4 5
J M Dixon consultant surgeon and senior lecturer
Academic Office, Edinburgh Breast Unit, Western
General Hospital, Edinburgh EH4 2XU
jmd@wght.demon.co.uk
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Schizophrenia in ethnic
minority groups
Selection bias in prevalence data is
difficult to rule out
Editor—To sociologists, Boydell et al’s find›
ings are counterintuitive.1 One would expect
economic deprivation (at neighbourhood
level) to be a decisive factor for an increased
incidence of mental illness. But it is surpris›
ing to learn that the lower the proportion of
non›white ethnic minorities in a local area
the higher the incidence of schizophrenia in
those minorities (controlled for economic
deprivation).
As an explanatory hypothesis the
authors point to overt discrimination and
institutionalised racism as sources of stress,
which can be alleviated by people making
use of social capital within the ethnic group.
This hypothesis surely necessitates further
testing and debate. It is a pity that non›white
ethnic minority groups had to be considered
as one homogeneous group on an aggre›
gate level. The social networks and levels of
social cohesion may be different for different
ethnic groups, and follow up research
should be able to distinguish these.
Boydell et al assume that all people with
schizophrenia will come into contact with
psychiatric services, but this requires closer
attention. Members of an ethnic minority
with a mental disorder who live in predomi›
nantly white neighbourhoods may be more
likely to come into contact with psychiatric
services. Probing for mental disorders
might be more likely in predominantly
white neighbourhoods than in non›white
neighbourhoods. This is not necessarily
ruled out by the fact that there is job mobil›
ity of clinical staff, since institutional
cultures can both consciously and uncon›
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sciously shape and influence individual
professional practice (and in fact necessitate
individual adaptation).
Different processes of self selection in
contacting health services or looking for
particular types of treatment may operate in
different areas. It might be that in mainly
non›white neighbourhoods, which often are
also the most economically deprived areas,
mental health issues among non›white
groups are considered to be “luxury”
problems compared with other health or
social problems. As a result, incidences
might be underestimated. The risk of being
diagnosed as mentally ill in white (and often
better off) neighbourhoods might be higher
because of cultural›institutional factors.
The findings of this study are interesting.
Sociologists signal different levels of toler›
ance, or willingness to label someone as
deviant (for example, as “ill” or “insane”),
according to the social setting.2
Dirk Jacobs researcher
Institute of Political Sociology and Methodology
(IPSoM), Katholieke Universiteit van Brussel,
B›1081 Brussels, Belgium
dirk.jacobs@kubrussel.ac.be
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Authors’ reply
Editor—We agree that our findings are pre›
liminary and demand both replication and
further investigation. We are currently
studying social capital in the area and hope
to be able to measure this separately for the
larger ethnic minority groups. Regarding
the problem of selection bias, we examined
incidence (number of new cases) not preva›
lence (total number of cases). Several
studies, including one from the area we
studied, have shown that a very high
percentage of people with schizophrenia
come into contact with psychiatric
services.1–3 Furthermore in our study most
incident cases were admitted via emergency
psychiatric services provided centrally for
the whole area. We therefore consider it very
unlikely that institutional factors and label›
ling phenomena have influenced our results.
As schizophrenia is still highly stigma›
tised we do not believe that non›whites in
the smaller groups selected themselves for
hospitalisation. Similarly, the very high rates
of compulsory admission are against the
view that schizophrenia is considered a
“luxury” problem in our local community. It
is, of course, never possible to completely
rule out selection bias, as we discussed in the
paper, but the magnitude of our findings
give us confidence in the conclusion that the
smaller the minority, the greater the
incidence of schizophrenia.
J Boydell clinical researcher
R M Murray professor of psychiatry
Division of Psychological Medicine, Institute of
Psychiatry, London SE5 8AF
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Antiplatelet therapy and
atherosclerotic events
Commentary is inaccurate
Editor—We endorse the response of Bai›
gent and others to Cleland’s commentary
on the Antithrombotic Trialists’ antiplatelet
meta›analysis.1–3 We would like to add some
further comments in response to Cleland’s
article and the editorial in the same issue.4
Both suggest that the data in the
meta›analysis were revised retrospectively.
But the overview methods were planned
prospectively. Differences between the data
in trial publications and the dataset used for
the meta›analysis occurred where trialists
provided additional information on the
numbers of patients originally randomised,
or on unpublished or subsequently available
outcomes for small numbers of patients.
Minor differences between the current and
previous antiplatelet overviews generally
relate to additional, unpublished data from a
few trials and do not affect any of the results
or conclusions.
The claim by Reilly and FitzGerald that
the absolute reduction in vascular events
with antiplatelet treatment is smaller in
acute ischaemic stroke than in other high
risk conditions is incorrect. For every 1000
patients treated, about 10 events are
prevented in the first month after onset of
stroke, and just over one event per month is
prevented with long term treatment thereaf›
ter.3
Cleland finds it remarkable how seldom
trials of antiplatelet agents have shown ben›
efit on their selected primary outcome.
Many early trials of antiplatelet treatment
were too small to detect moderate benefits
reliably, which is why the first meta›analyses
were needed. Reilly and FitzGerald suggest
that meta›analysis is no longer needed
because large enough trials are now being
done. This view fails to acknowledge that,
firstly, meta›analysis of large trials can assess
not just whether a treatment works but also
for whom and by how much, and, secondly,
trials comparing different antiplatelet regi›
mens have rarely been large enough to
detect the small differences expected.
Cleland says that inconvenient trials are
ignored in the discussion section of the
meta›analysis, citing an unpublished anti›
thrombotic trial, which included fewer than
200 patients and recorded only about 50
vascular events in its comparison between
aspirin and control. Including this trial in
the meta›analysis would make no difference
to the results. Cleland also cites an economic
appraisal of aspirin, which he co›authored.
Its first sentence, that aspirin is a cheap drug
that is effective for the prophylaxis of cardio›
vascular events, contrasts with the views in
Cleland’s commentary.
Finally, unlike the Antithrombotic Trial›
ists’ meta›analysis, neither the accompany›
ing editorial nor the commentary has been
endorsed by hundreds of collaborating trial›
ists worldwide. Furthermore, Cleland’s com›
mentary was published despite a reviewer
pointing out that his views are maverick, and
despite the fact that the conclusions of his
article rely on basic errors of fact.2
Cathie Sudlow Wellcome clinician scientist
csudlow@skull.dcn.ed.ac.uk
Peter Sandercock professor of medical neurology
Charles Warlow professor of medical neurology
Department of Clinical Neurosciences, University
of Edinburgh, Western General Hospital,
Edinburgh EH4 2XU
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Risks and patients’ values need to be
included in decision about aspirin for
prevention of coronary heart disease
Editor—The updated meta›analysis by the
Antithrombotic Trialists’ Collaboration con›
firms the benefits of aspirin in reducing
non›fatal myocardial infarction, non›fatal
stroke, vascular deaths, and total mortality in
patients at high risk of vascular events.1 High
risk was defined as patients with previous
occlusive events or predisposing conditions
(for example, diabetes) that led to risks of
having a vascular event that were greater
than 3% per year.
On the basis of these findings, the
authors recommended aspirin for patients
with high cardiovascular risks and low or
average risks of gastrointestinal bleeding. In
their discussion, they also recommended
aspirin for patients at intermediate risk of
vascular events (annual risk of 2›3%), includ›
ing those with peripheral vascular disease,
stable angina, or atrial fibrillation. They then
concluded by saying that for most healthy
people, for whom the risk of a vascular event
is likely to be substantially less than 1% per
year, daily aspirin may well be inappropriate.
We performed a systematic review and
meta›analysis of the effect of aspirin in
adults with no previous history of cardiovas›
cular events for the US Preventive Services
Task Force.2 On the basis of the results of five
large trials that evaluated the use of aspirin
for patients without cardiovascular disease,
we concluded that aspirin reduced the risk
of non›fatal myocardial infarction and
deaths from coronary heart disease by 28%.
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Aspirin had little effect on thrombotic
strokes or all›cause mortality over the three
to seven year duration of the trials. The risk
of coronary heart disease of patients in the
five trials ranged from 0.36% to 1.24% per
year, well below the high risk patients
studied in the BMJ review. We found that the
harms of aspirin included increased risks of
haemorrhagic stroke and gastrointestinal
bleeding that were similar to the levels found
in the trials with patients at high risk.
We concluded that the number of
potential reductions in events of coronary
heart disease exceeded the number of
potential precipitated adverse bleeding
events when patients have an annual risk of
1% or greater of events of coronary heart
disease. Numbers of adverse effects
approached the numbers of beneficial
effects when the annual risk of coronary
heart disease was 0.2% or less. The balance
of beneficial and adverse effects was closer
for patients with risks of 0.2›1.0% per year.
Providers and patients can easily measure
such risks by using any one of several
cardiovascular risk calculators available on
the web, including our own site (www.med›
decisions.com). We recommend that provid›
ers and patients incorporate both risk and
patient values about those risks into their
decisions regarding whether or not to use
aspirin.
Michael Pignone assistant professor of medicine
University of North Carolina›Chapel Hill, 5039 Old
Clinic Building, UNC Hospital, Chapel Hill, NC
27599›7110, USA
pignone@med.unc.edu
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Fortification of flour with
folic acid
Fortification has several potential risks
Editor—Wharton and Booth recommend
caution and carrying out a field trial before a
policy of fortifying flour with folic acid is
implemented, but both they and the Depart›
ment of Health’s report understate the
potential risks of the policy to the nervous
system.1
In people with vitamin B›12 deficiency,
giving folic acid does much more than mask
any anaemia. The response of pernicious
anaemia to folic acid is usually suboptimal
and temporary and often followed by
relapse. The vitamin precipitates not only
neurological complications, sometimes after
some initial temporary improvement, but
also anaemia, although not necessarily to
the same degree or in the same time scale.2 3
Can these problems with usually phar›
macological doses of folic acid (1›50 mg
daily) be avoided with minimum food
fortification? The only evidence I know of is
a review of 38 patients with vitamin B›12
deficiency treated with <1 mg folic acid,
30% of whom showed a significant haemato›
logical response. None of 25 patients treated
for 7›19 days developed nervous system dis›
order, whereas six of 12 treated for 90›930
days did. Isolated examples of a reticulocyte
response and neurological deterioration
occurred with doses as low as 0.3›0.5 mg
daily.4 Because of the very active blood›brain
barrier for folate the vitamin enters the
nervous system slowly and the duration of
treatment is just as important as the dose,
which is highly relevant to food fortifica›
tion.3 5
Folic acid does much more than
interfere with the metabolism of antiepilep›
tic drugs. Experimental studies have con›
firmed that folates are highly convulsant if
the blood›brain barrier is circumvented. The
risk to patients is small because of the
barrier mechanism, but the bigger the dose,
the longer the duration, and the greater the
damage to the blood›brain barrier then the
higher the risk.
I do not agree that the benefits of fortifi›
cation are clear. They may be relatively clear
with respect to the prevention of neural tube
defects, but not all such defects are prevent›
able with folic acid. The Department of
Health’s report estimates that fortification
with 240 ìg folic acid/100 g flour would
prevent a further 74 cases (41%) in the
United Kingdom. Given the potential risks
to others, the policy of universal food fortifi›
cation seems disproportionate.
Other, potentially much greater benefits
of food fortification exist (including in
vascular disease and to mental health),
which have yet to be clarified. The possible
benefits for mood, cognitive function, and
ageing are considerable but have not been
evaluated.3 5
For all these reasons field trials are
advisable before the whole population is
exposed to a prolonged increase in folate
intake.
Edward Reynolds consultant neurologist
Institute of Epileptology, King’s College, Weston
Education Centre, London SE5 9PJ
reynolds@buckles.u›net.com
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Fortification is needed now
Editor—Wharton and Booth raised several
points about the safety of fortifying food
with folic acid to prevent neural tube
defects.1 In my opinion, the negative effects
of food fortification are overstated.
The risk of folate masking B›12 defi›
ciency leading to spinal cord degeneration is
probably low.2 It is well known that neuropa›
thies due to B›12 or folate deficiency can
occur without megaloblastic anaemia.
Surely an increase in cord degeneration
would have been seen by now in the United
States, where food has been fortified since
1998. Even if it was increased, this risk could
be abrogated by food fortification with
vitamin B›12 in addition to folate.3
Interference with antiepileptic drugs is
unlikely to occur at the levels of fortification
proposed. As the risk of fetal abnormality is
increased in people with epilepsy who are
taking drugs, especially in those taking
sodium valproate, folate supplementation in
this group is even more important.
Although it is mentioned in the edito›
rial, not enough weight is given to the effect
of folic acid in reducing plasma homo›
cysteine concentration, an emerging risk
factor for atherosclerosis. Many case›control
studies show that patients with high homo›
cysteine concentrations are at increased risk
from ischaemic heart disease and stroke,
probably because of direct vascular
endothelial damage.4 The potential positive
effects of folate on the vascular endothelium
have been shown in recent short term
randomised controlled trials in high risk
groups.5
More extensive trials are ongoing, but
they will probably show a magnitude of ben›
efit similar to that estimated by case›control
studies. As 10›20% of the population have
high homocysteine concentrations, and this
proportion increases with age, the potential
health improvements are large and are likely
to much outweigh the theoretical negative
effects mentioned in the editorial.
A controlled trial of folate fortification,
as suggested, would have to be conducted
over an extended period to show the
positive and negative effects adequately.
During this time, preventable morbidity and
death from atherosclerotic disease would be
likely and many women would have
unnecessary second trimester terminations.
Folic acid fortification should be started as
soon as possible.
Mark Sillender specialist registrar in obstetrics and
gynaecology
Royal Berkshire Hospital, Reading, Berkshire
RG1 5AN
marksillender@hotmail.com
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Treatment of intersex needs
open discussion
Editor—It is excellent to see surgery for
ambiguous genitalia and intersex being
openly discussed.1–5 These articles prove
what patients have been saying for years,
that surgery can, and does, cause damage to
sexual function. This research is long
overdue and most welcomed by patients and
parents. I agree that cosmetic genital surgery
needs to be reassessed.
Parents and patients need to have all the
facts explained before opting for irreversible
genital surgery. This is especially so in the
changing NHS that is aiming to be more
patient led. Fully informed consent is
important (particularly after the Bristol and
Alder Hey scandals), and may be lacking in
patients with ambiguous genitalia or inter›
sex as surgery is often done on children
before they can give consent. If parents are
to make these decisions they need the full
facts or they will end up with feelings of
extreme guilt for damaging their child’s
sexual function by having early surgery.
Ambiguous genitalia or intersex are nothing
to be ashamed of; being more open can only
help people lead better lives. More research
is needed into whether leaving surgery until
adolescence will have psychological effects
compared with surgery in early infancy as is
current practice in the thought that it
reinforces sexual identity. This gives rise to
the necessity for multidisciplinary treatment
centres to treat the conditions with a more
holistic approach encompassing surgery,
endocrinology, and psychology.
Two conferences in 2000 brought
together professionals and patient support
groups to present their views. Universities
have also invited patient groups to speak to
medical students to learn from patients the
effect on lives of people with ambiguous
genitalia.
Support groups are professional and
not disgruntled haters of doctors. They work
closely with the medical profession to
improve treatment, raise awareness, and
support patients. Patients have the oppor›
tunity to air their views only in the media,
which can often distort important issues.
When doctors come to our conferences
and take time to listen to patients, parents,
and support groups, they learn more than
they do in the few minutes of a consultation.
Patients are more likely to open up and talk
to doctors who take an interest in how con›
ditions affect people’s quality of life and eve›
ryday living.
Melissa Cull founder, Adrenal Hyperplasia Network
17 Newton Road, Lichfield, Staffordshire
WS13 7EF
melissa.cull@mlcull.demon.co.uk
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2 Creighton SM, Minto CL, Steele SJ. Objective cosmetic
and anatomical outcomes at adolescence of feminising
surgery for ambiguous genitalia done in childhood. Lancet
2001;358:124›5.
3 Creighton SM. Surgery for intersex. J Royal Soc Med
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4 Creighton SM, Minto CL. Managing intersex. BMJ
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Doctors’ knowledge of
radiation exposures is deficient
Editor—We read with interest Adams’s per›
sonal view and share her concerns.1 At one
of our hospitals a young boy with splenic
trauma received serial computed tomogra›
phy scanning of his upper abdomen to
assess the degree of splenic laceration. The
scans were discussed at a multiple discipli›
nary meeting, and a query was raised
regarding the radiation dose received by
that patient. It became clear that the request›
ing doctors were unaware of the dose.
We compiled a simple questionnaire
and interviewed 130 doctors of all grades,
including consultant radiologists. They were
asked for an approximate dose of radiation
to the average patient having chest radio›
graphy. This was then used as a unit of 1 to
calculate how many units a patient would
receive for a wide variety of investigations
carried out in a busy radiology department
of a district general hospital (17 examina›
tions in total).
The results were appalling. With a pass
mark of 50% only three doctors (2%) passed,
and that was with a generous marking
scheme—20% error allowed and no negative
marking. Many doctors were able to score at
all only because they realised that ultra›
sound examinations do not use ionising
radiation. The degree of knowledge was
inversely proportional to seniority, with con›
sultants scoring less than junior colleagues.
It was clear and worrying that doctors have
no real knowledge of radiation doses that
their patients receive.
The fact that computed tomograms of
the entire body can be performed on a single
breath hold over a matter of seconds does not
mean the patient is getting a lower radiation
dose than they would have received 10 years
ago. Although the Ionising Radiation (Medi›
cal Exposure) Regulations 2000 are in place,
which means that it is a legal requirement to
keep radiation exposures as low as possible
and that they should be justifiable, it seems
that knowledge is still seriously lacking.
K Gower›Thomas consultant radiologist
Kgthomas@pr›tr.wales.nhs.uk
M H Lewis consultant surgeon
Royal Glamorgan Hospital, Ynysmaerdy,
Llantrisant, Mid Glamorgan CF72 8XR
S Shiralkar specialist registrar in surgery
University Hospital of Wales, Cardiff, CF14 4XW
M Snow specialist registrar in Orthopaedics
Royal Gwent Hospital, Cardiff Road, Newport
NP9 2UB
R B Galland consultant surgeon
Royal Berkshire Hospital, Reading RG1 5AN
A Rennie specialist registrar in radiology
John Radcliffe Hospital, Oxford OX3 9DZ
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Prevalence of surnames in
each letter affects order of
authors
Editor—Chambers et al’s study of the order
of authorship in a study seems to be lacking
in at least one way.1 I have observed that sur›
names, especially those with a British origin,
tend to begin with letters from the first half of
the alphabet. For example, among the
research group to which I belong, surnames
begin with A, A, B, C, H, J, K, L, L, L, M, P, R, R,
S, and S. According to probability, a random
drawing of three of my colleagues’ names to
determine the order of authorship would be
more likely to result in the first author having
a surname beginning with a letter in the first
half of the alphabet than in the second.
The graph in Chambers et al’s paper
presents only the percentages of names in
their study; it does not indicate (except for Q
and X) what the prevalence was for
surnames beginning with each letter. Thus it
unfortunately does not allow us to evaluate
whether adjustments are needed. This study
could be enhanced by adjusting the analysis
for the higher prevalence of surnames that
begin with first letters from the first half of
the alphabet.
Benjamin D Horne epidemiologist
LDS Hospital, Salt Lake City, UT 84103, USA
ldbhorne@ihc.com
1 Chambers R, Boath E, Chambers S. The A to Z of author›
ship: analysis of influence of initial letter of surname on
order of authorship. BMJ 2001;323:1460›1. (22›29
December.)
Advice to authors
We prefer to receive all responses electronically,
sent directly to our website. Processing your letter
will be delayed unless it arrives in an electronic
form.
We are now posting all direct submissions to
our website within 24 hours of receipt and our
intention is to post all other electronic
submissions there as well. All responses will be
eligible for publication in the paper journal.
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